Researchers have developed a one-time injection that permanently lowers LDL cholesterol by targeting the underlying genetic mechanism responsible for high cholesterol production. Recent clinical trial data shows the drug reduces LDL levels by 62 percent in patients who take it once.
The treatment works through a novel mechanism called RNA interference, which silences the PCSK9 gene. This gene produces a protein that prevents the body from removing LDL cholesterol from the bloodstream. By turning off PCSK9 production, the drug allows the body's natural cholesterol-removal systems to work more effectively.
The one-time dosing represents a major shift from current cholesterol management. Most people with high cholesterol take daily or weekly medications like statins or PCSK9 inhibitor injections that require ongoing treatment. A permanent solution could transform care for patients with familial hypercholesterolemia, a genetic condition affecting roughly one in 250 people, and those with stubborn high cholesterol despite medication.
The 62 percent reduction in LDL cholesterol observed in the trial exceeds what many existing drugs achieve. For context, statins typically lower LDL by 30 to 50 percent, while newer PCSK9 inhibitors reduce it by 40 to 60 percent. What distinguishes this new approach is the single-dose administration that appears to provide lasting effects.
Patients with familial hypercholesterolemia face dramatically elevated heart attack and stroke risk starting in their 20s and 30s if left untreated. Current therapies require lifelong adherence, which can prove challenging. A one-time treatment removes barriers to consistent care and could save lives by ensuring cholesterol stays controlled without daily compliance burden.
The drug still requires FDA approval and broader clinical testing before reaching patients. Researchers must confirm the treatment's long-term safety profile